Last updated on September 2017

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC


Brief description of study

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

Detailed Study Description

This randomized phase III trial studies sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with liver cancer that has spread to nearby tissue or lymph nodes or has spread to other places in the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving sorafenib tosylate together with doxorubicin hydrochloride is more effective than sorafenib tosylate alone in treating liver cancer.

For Study Locations, Click Here

Clinical Study Identifier: TX152916

Contact Investigators or Research Sites near you

Start Over

Research Center

Research Center
Additional Locations, MN USA
  Connect »